|
|
Volumn 24, Issue 9, 2002, Pages 711-715
|
|
The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CONJUGATED ESTROGEN;
MEDROXYPROGESTERONE ACETATE;
AGE;
AGED;
ARTICLE;
BREAST TUMOR;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
EPIDEMIOLOGY;
ESTROGEN THERAPY;
FEMALE;
HUMAN;
METHODOLOGY;
MIDDLE AGED;
POSTMENOPAUSE;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
WOMEN'S HEALTH;
AGE FACTORS;
AGED;
BREAST NEOPLASMS;
CARDIOVASCULAR DISEASES;
CONFOUNDING FACTORS (EPIDEMIOLOGY);
ESTROGEN REPLACEMENT THERAPY;
ESTROGENS, CONJUGATED (USP);
FEMALE;
HUMANS;
MEDROXYPROGESTERONE 17-ACETATE;
MIDDLE AGED;
POSTMENOPAUSE;
PROSPECTIVE STUDIES;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH DESIGN;
RISK ASSESSMENT;
WOMEN'S HEALTH;
|
|
EID: 0036731679
PISSN: 17012163
EISSN: None
Source Type: Journal
DOI: 10.1016/S1701-2163(16)30326-7 Document Type: Article |
|
Times cited : (54)
|
|
References (0)
|
